CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

相似書籍

• Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
  由: Xu-Monette, Zijun Y., et al.
  出版: (2019)
• XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
  由: Manman Deng, et al.
  出版: (2020-11-01)
• XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
  由: Deng, Manman, et al.
  出版: (2020)
• A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
  由: Xu-Monette, Zijun Y., et al.
  出版: (2020)
• MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
  由: Hu, Shimin, et al.
  出版: (2013)